8-K: Revvity Exceeds Q4 Expectations, Forecasts 2026 Growth

Revvity, Inc. reported strong fourth-quarter and full-year 2025 financial results, surpassing expectations and initiating optimistic 2026 guidance.

Summary

• Fourth quarter 2025 revenue reached $772 million, representing a 6% increase year-over-year and 4% organic growth.
• GAAP earnings per share (EPS) for Q4 2025 was $0.87, up from $0.78 in the prior year period.
• Adjusted EPS from continuing operations for Q4 2025 was $1.70, an increase from $1.42 in the same period a year ago.
• Full year 2025 revenue totaled $2,856 million, compared to $2,755 million in 2024.
• Full year 2025 GAAP EPS was $2.07, a decrease from $2.20 in 2024.
• Adjusted EPS from continuing operations for the full year 2025 was $5.06, up from $4.90 in 2024.
• The Life Sciences segment reported Q4 2025 revenue of $382 million (up 2%, organic revenue flat) and full year revenue of $1,431 million (up 2%, 2% organic).
• The Diagnostics segment reported Q4 2025 revenue of $390 million (up 10%, 7% organic growth) and full year revenue of $1,425 million (up 5%, 4% organic).
• Revvity initiated full year 2026 guidance, forecasting total revenue of $2.96-$2.99 billion, organic revenue growth of 2-3%, and adjusted EPS of $5.35-$5.45.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong adjusted earnings, robust Q4 performance, and optimistic 2026 guidance, despite some GAAP declines and flat organic growth in Life Sciences.

Positives

• Strong Q4 2025 revenue growth of 6% year-over-year, with 4% organic growth.
• Significant increase in Q4 2025 Adjusted EPS from continuing operations to $1.70, up from $1.42.
• Full year 2025 Adjusted EPS from continuing operations increased to $5.06, compared to $4.90 in 2024.
• The Diagnostics segment demonstrated robust performance with 10% revenue growth and 7% organic revenue growth in Q4 2025.
• Management stated that the company finished 2025 on a strong note, delivering results "solidly ahead of our expectations".
• The company provided an optimistic full year 2026 guidance, projecting continued growth in total revenue, organic revenue, and adjusted EPS.

Negatives

• Q4 2025 GAAP operating income from continuing operations decreased to $112 million from $119 million in the prior year period.
• Q4 2025 GAAP operating profit margin from continuing operations declined to 14.5% from 16.3% year-over-year.
• Full year 2025 GAAP EPS decreased to $2.07 from $2.20 in 2024.
• Full year 2025 Adjusted operating income slightly decreased to $773 million from $779 million in 2024.
• Full year 2025 Adjusted operating profit margin declined to 27.1% from 28.3% in 2024.
• The Life Sciences segment's organic revenue was flat in Q4 2025.
• Cash and cash equivalents decreased to $919,860 thousand at December 28, 2025, from $1,163,396 thousand at December 29, 2024.
• The current portion of long-term debt significantly increased to $588,828 thousand at December 28, 2025, from $242 thousand at December 29, 2024.

Risks

• Markets into which products are sold may decline or not grow as anticipated.
• Fluctuations in the global economic and political environments, including as a result of recently implemented and threatened tariff increases.
• Failure to introduce new products in a timely manner.
• Inability to execute acquisitions and divestitures, license technologies, or successfully integrate acquired businesses or licensed technologies into existing businesses or make them profitable.
• Inability to compete effectively.
• Fluctuation in quarterly operating results and inability to adjust operations to address unexpected changes.
• Significant disruption in third-party package delivery and import/export services or significant increases in prices for those services.
• Disruptions in the supply of raw materials and supplies.
• Inability to retain key personnel.
• Significant disruption in information technology systems, or cybercrime.
• Inability to realize the full value of intangible assets.
• Failure to adequately protect intellectual property.
• Loss of any licenses or licensed rights.
• The manufacture and sale of products exposing the company to product liability claims.
• Failure to maintain compliance with applicable government regulations.
• Failure to comply with data privacy and information security laws and regulations.
• Regulatory changes.
• Failure to comply with healthcare industry regulations.
• Economic, political, and other risks associated with foreign operations.
• Inability to obtain future financing.
• Restrictions in credit agreements.
• Significant fluctuations in stock price.
• Reduction or elimination of dividends on common stock.

Future Outlook

Revvity forecasts full year 2026 total revenue between $2.96 billion and $2.99 billion, with organic revenue growth projected at 2-3%, and adjusted earnings per share expected to be in the range of $5.35 to $5.45. Management believes its portfolio transformation positions the company well to capitalize on improving end market conditions.

Management Comments

• "We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations."
• "Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come."

Industry Context

StockSavvy.ai notes that Revvity's focus on health science solutions, particularly in translational multi-omics, biomarker identification, and diagnostics, aligns with the broader industry trend towards precision medicine and advanced analytical tools. The company's ability to deliver strong adjusted earnings and provide positive guidance suggests resilience in a competitive market, potentially outperforming peers facing similar economic headwinds.

Comparison to Industry Standards

• The filing does not provide specific comparable company or project data to allow for a detailed assessment against global benchmarks.

Stakeholder Impact

• Shareholders: Positive Q4 adjusted results and optimistic 2026 guidance could lead to increased investor confidence and potential share price appreciation. The decrease in GAAP EPS and operating margins, however, might warrant scrutiny.
• Employees: The
• transformation costs
• and "restructuring and other charges" mentioned in non-GAAP adjustments could imply ongoing organizational changes, potentially impacting employees.
• Customers: Continued investment in health science solutions and technologies suggests ongoing product development and service improvements.
• Creditors: The significant increase in the current portion of long-term debt from $242 thousand to $588,828 thousand could be a point of interest, though overall long-term debt decreased.

Next Steps

• The company will discuss its fourth quarter and full year 2025 results and its outlook for business trends during a webcast on February 2, 2026, at 8:00 a.m. Eastern Time.

Key Dates

Recommendation

The company delivered strong adjusted financial results for Q4 and full year 2025, exceeding management's expectations. The positive 2026 guidance, particularly in organic revenue growth and adjusted EPS, indicates a healthy outlook. While GAAP metrics show some declines, the focus on adjusted figures, which management uses for operational decisions, suggests underlying business strength and effective portfolio transformation. The robust performance of the Diagnostics segment further supports a positive investment thesis, making it a compelling 'buy' for investors looking for growth in the health science sector.

Keywords

Revvity, RVTY, Financial Results, Earnings, Q4 2025, Full Year 2025, 2026 Guidance, Life Sciences, Diagnostics, Organic Growth, EPS, Revenue, Operating Income, SEC Filing, Healthcare, Biotech, Medical Devices